Faced with these hurdles to gain global market access in the constantly shifting healthcare landscape?
GMAS provides on-demand access to DRG’s expertly curated Global Market Access datasets, country benchmarking tools, commercially focused country-specific analysis on 29 counties, and the first managed entry agreement (MEA) global database.
Continuously updated by country market experts as new data emerges, GMAS allows users to gain a clear understanding of the complex and evolving drivers and barriers to successful global market access by staying abreast of market shifts, key decision-makers, and trends that affect the market access landscape.
GMAS equips biopharma teams with critical insights to:
Four integrated sections provide a detailed deep-dive comparative country analysis, including healthcare systems and processes/details for market authorization, pricing, reimbursement, pharmacoeconomic analysis, and cost-containment strategies.
Geographic Focus – Country summaries and analysis to build country-specific effective market access plans.
Therapeutic Focus – Epidemiology, mortality, and global burden of disease data to identify market opportunities.
Commercial Attractiveness – Proprietary tools for comparative benchmarking to mitigate risk and prioritize assets.
Insights Library – Rich, expertly curated knowledge-sharing documents to explore given markets.
MEAs are reshaping the contracting landscape. Now the industry’s only global MEA database with qualitative insights empowers users with the critical intelligence necessary to map out an effective strategy to secure favorable reimbursement.
The GMAS MEA database enables all users to:
DRG creates enduring working relationships with a focus on collaboration and thought partnership to facilitate our clients’ pursuit of global market access. With a bench of commercially focused analysts and thought leaders—and an industry-leading Client Experience (CE) team—GMAS enables clients to easily: